Financial Data and Key Metrics Changes - Revenue for Q4 2020 increased sequentially by approximately $1 million, or 78% compared to Q3 2020, despite the impact of COVID-19 [7] - Total revenue for the year ended December 31, 2020, was $5.4 million, down from $8.3 million for the same period last year [26] - Gross profit for the year ended December 31, 2020, was $3.6 million or 76% of revenue, compared to $5.7 million or 68% of revenue for the year ended December 31, 2019 [27] - Operating loss for the year ended December 31, 2020, was approximately $7.5 million, compared to approximately $4 million for the year ended December 31, 2019 [28] - Net loss was approximately $7.3 million or $0.12 per share for the year ended December 31, 2020, versus a net loss of $7.5 million or $0.16 per share for the comparable period in 2019 [28] - Cash and cash equivalents as of December 31, 2020, were approximately $14.2 million [29] Business Line Data and Key Metrics Changes - Dental revenue decreased by approximately $2.9 million due to the impact of the COVID-19 pandemic [26] - Medical revenue for the 12 months ended December 31, 2020, was approximately $16,000, down from $38,000 for the year ended December 31, 2019 [26] - The company has begun selling CompuFlo Epidural and CathCheck disposables to several premier medical centers, indicating a positive trend in medical sales [9][10] Market Data and Key Metrics Changes - The company entered into an agreement with Bitmedical AG to distribute the CompuFlo Epidural instrument and CathCheck system in Switzerland and Austria, expanding its market presence [11] - A group purchasing agreement was awarded for CompuFlo and CathCheck with Premier, a leading group purchasing organization, which includes approximately 4,100 U.S. hospitals [12] Company Strategy and Development Direction - The company is focusing on expanding its dental business through a decentralized sales strategy, targeting independent distributors [21][22] - The strategy includes increasing the placement of the Wand STA instrument and expanding dental disposables [23] - The company aims to become the new standard of care in epidural procedures, with a focus on the CompuFlo Epidural system [10][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the recovery of the dental business and the potential for growth in the medical sector [31] - The company is confident in the market potential of the CompuFlo Epidural, which is expected to transform the industry [31] - Management highlighted the importance of their strong financial position, with over $14 million in cash and cash equivalents, to support growth initiatives [32] Other Important Information - The company received two notices of allowance for key patents from the U.S. Patent and Trademark Office and the European Patent Office, enhancing its intellectual property portfolio [15][16] - The company is actively engaged in hiring sales professionals to enhance its rollout in the U.S. [19] Q&A Session Summary Question: Can you discuss the pilot programs and sales rep expansion? - Management indicated that they held off on significant hiring until they had success in at least two hospitals, which has now occurred, leading to an expansion of the sales force [35][36] Question: What is the current access to hospitals? - Access is still a mix, but the trend is encouraging as hospitals are reopening and allowing sales teams back in [42] Question: How has the GPO relationship facilitated hospital meetings? - The GPO relationship has helped reduce barriers to hospital access, facilitating introductions and endorsements [47][48] Question: What is the status of manufacturing and potential hurdles? - The dental instrument is produced in the U.S., while disposables are produced in China, with no anticipated difficulties in manufacturing [63][66] Question: What are the implications of the recent patent announcement? - The patent opens up new possibilities for the company, particularly in the peripheral nerve block market, which has a larger addressable market [76][79]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020. Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware 13-3545623 State or other jurisdicti ...

Milestone Scientific, Inc. (NYSE:MLSS) Q3 2020 Earnings Conference Call November 17, 2020 8:30 AM ET Company Participants David Waldman - IR, Crescendo Communications, LLC Leonard Osser - Interim Chief Executive Officer & Director of China Operations Arjan Haverhals - President & Chief Executive Officer of Wand Dental Inc. Joseph D'Agostino - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group James Terwilliger - Northland Capital Markets Operator Greetings, and welcome to Mi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware 13-3545623 State or other jurisdiction o ...

Milestone Scientific, Inc. (NYSE:MLSS) Q2 2020 Earnings Conference Call August 17, 2020 8:30 AM ET Company Participants David Waldman - IR, Crescendo Communications, LLC Leonard Osser - Interim Chief Executive Officer & Director of China Operations Arjan Haverhals - Chief Executive Officer of Wand Dental Inc. Joseph D'Agostino - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group James Dowling - Jefferies Capital Operator Greetings. Welcome to the Milestone Scientific Second ...

Sales Performance - The total product sales for the six months ended June 30, 2020, were $1,979,060, a decrease from $4,173,759 in the same period of 2019, reflecting a significant decline in demand due to the COVID-19 pandemic[142]. - Domestic sales in the U.S. for devices dropped to $525 in 2020 from $232,205 in 2019, while handpieces sales decreased to $635,490 from $1,597,316[142]. - International sales for devices were $281,904 in 2020 compared to $665,068 in 2019, and handpieces sales fell to $1,018,123 from $1,485,067[142]. - For the three months ended June 30, 2020, net product sales were $167,674, a decrease of 92.57% compared to $2,257,851 in 2019[144]. - For the six months ended June 30, 2020, total net sales were $1,979,060, a decrease of 52.58% from $4,173,759 in 2019[145]. Profit and Loss - Gross profit for the same period was $112,048, down 92.56% from $1,505,668 in 2019[148]. - Gross profit for the six months was $1,363,734, down 51.35% from $2,802,883 in 2019[154]. - The net loss for the three months ended June 30, 2020, was $3,178,202, compared to a net loss of $1,053,243 in 2019[144]. - The total loss from operations for the six months ending June 30, 2020, was approximately $4.7 million, an increase of 148.26% compared to a loss of $1.9 million in the same period of 2019[157]. Expenses - Selling, general and administrative expenses increased to $3,176,768, a rise of 26.16% from $2,517,970 in 2019[149]. - Research and development expenses for the six months increased to $215,650, a significant rise of 111.68% from $101,875 in 2019[156]. Cash Flow - Cash flow from operating activities for the six months ended June 30, 2020, was a net cash used of $4,111,504, compared to $622,279 in 2019[145]. - Negative cash flows from operating activities for the six months ended June 30, 2020, were approximately $4.2 million, compared to $622,000 for the same period in 2019[158]. - The company had cash and cash equivalents of approximately $16.6 million and working capital of approximately $16.5 million as of June 30, 2020, compared to $1.2 million in working capital on December 31, 2019[158]. Impact of COVID-19 - The COVID-19 pandemic has led to a decrease in demand for the company's products, particularly in the dental and medical divisions, with potential long-term impacts on sales and operations[137]. - The company anticipates that revenue for the third and possibly fourth quarters will be materially and adversely affected due to COVID-19[147]. - The company is focusing on the commercialization of the CompuFlo Epidural System, which may be impacted by the ongoing pandemic[147]. Product Development and Market Expansion - The CompuFlo Epidural System achieved a 99% success rate in identifying the epidural space in a clinical trial involving 400 patients, demonstrating its effectiveness in labor and delivery[130]. - The company has expanded its global footprint by granting exclusive marketing and distribution rights for the Wand/STA Instrument to suppliers in various regions, including Asia, Africa, South America, and Europe[125]. - Milestone Scientific is transitioning from a research and development organization to a commercially focused medical device company following successful FDA clearances of its medical devices[123]. - The company has trained up to 25 exclusive product sales specialists to promote the Wand/STA instrument and handpieces in the U.S. market[123]. - The CompuFlo Epidural Trainer was introduced to the medical education market to improve epidural placement success, with distribution agreements signed with American 3B Scientific[133]. - The company is focused on expanding applications for its DPS Dynamic Pressure Sensing technology platform, aiming to establish it as the standard-of-care in drug delivery[123]. - The CompuFlo Epidural System has obtained FDA clearance, allowing the company to establish distribution in the U.S.[161]. - The company plans to restart the 510K application process for the intra-articular device later this year, subject to available internal resources[161]. Financing Activities - In April 2020, the company completed a Common Stock Offering generating gross proceeds of approximately $5.1 million, followed by a second offering in June 2020 generating approximately $14.6 million[159]. - The combined price of shares and warrants in the April offering was $0.95 per share, while in the June offering it was $2.15 per share[159]. - The company is actively pursuing positive cash flows through increased revenue from its dental and medical devices businesses, while considering other strategic plans[160].

Milestone Scientific, Inc. (NYSE:MLSS) Q1 2020 Results Earnings Conference Call May 18, 2020 8:00 AM ET Company Participants David Waldman - IR, Crescendo Communications, LLC Leonard Osser - Interim Chief Executive Officer, Director of China Operations Joseph D'Agostino - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Operator Greetings and welcome to the Milestone Scientific First Quarter 2020 Business Update Conference Call. At this time, all participants are in a list ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2020 Or Commission file number 001-14053 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware 13-3545623 State or other jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14053 Milestone Scientific Inc. (Exact name of registrant as specified in its charter) Delaware 13-3545623 State or other jurisdictio ...

Milestone Scientific Inc. (NYSE:MLSS) Q3 2019 Results Conference Call November 15, 2019 8:30 AM ET Company Participants David Waldman - IR Len Osser - Interim CEO Joseph D'Agostino - CFO Conference Call Participants Anthony Vendetti - Maxim Operator Good day and welcome to the Milestone Scientific Incorporated Third Quarter 2019 Investor Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr. David Waldman, Investor Relations. Please go ahead, sir. David Wal ...